Research Protocols
Longevity Quartet: MOTS-C + SS-31 + Semax + GHK-Cu | Artemis Labs
Longevity Quartet: MOTS-C + SS-31 + Semax + GHK-Cu — Multi-System Research Protocol
The Longevity Quartet combines four research peptides whose mechanisms target non-overlapping aging-biology systems — MOTS-C (mitochondrial biogenesis), SS-31 (mitochondrial optimization), Semax (neuroprotection), and GHK-Cu (tissue remodeling) — for multi-pathway longevity research protocols.
Research Highlights
- Four systems, four compounds, zero overlap: Each peptide dominates a distinct aging-biology axis, making the quartet a true multi-system rather than redundant stack.
- Mitochondrial bi-modal coverage: MOTS-C drives biogenesis (build new mitochondria); SS-31 optimizes existing mitochondria (cardiolipin binding, Complex I/IV efficiency). The pair covers both halves of the mitochondrial-aging problem.
- Neuro + tissue extensions: Semax preserves cognitive resilience through BDNF/NGF signaling; GHK-Cu maintains connective-tissue and gene-expression integrity. Together they extend the quartet beyond pure mitochondrial science.
Introduction: The Multi-System Approach to Aging
Aging is not a single biological process—it’s a convergence of multiple, overlapping dysfunctions across different biological systems. Mitochondrial energy production declines. Neurological signaling becomes less robust. Tissue remodeling efficiency drops. Vascular function deteriorates.
Single-target interventions address one mechanism. But aging is distributed across systems. The most compelling research direction in longevity science is multi-system intervention: using complementary compounds to address aging across mitochondria, neurons, vasculature, and connective tissue simultaneously.
This is the rationale behind the Longevity Quartet: four research peptides that target non-overlapping aging mechanisms. Together, they create a comprehensive longevity protocol that addresses aging at its roots—cellular energy production, neurological function, tissue integrity, and vascular health.
The Four Aging Pathways: A Framework
Aging research has converged on several key mechanistic pathways that drive age-related decline:
| Pathway | Primary Problem | Key Mechanism | Quartet Peptide |
|---|---|---|---|
| Mitochondrial Dysfunction | Energy production (ATP) declines; ROS accumulates | Reduced AMPK signaling; impaired electron transport | MOTS-C |
| Bioenergetic Crisis | Cardiolipin oxidation; ETC damage; ATP collapse | Mitochondrial membrane destabilization | SS-31 |
| Neurological Decline | Cognitive function, neuroplasticity, BDNF signaling | Reduced growth factor signaling; synapse loss | Semax |
| Tissue Remodeling Failure | Collagen cross-linking; connective tissue stiffness | Impaired gene expression; reduced enzyme activity | GHK-Cu |
These are distinct pathways. A single peptide cannot address all four. But together, the Longevity Quartet creates a synergistic system targeting aging at multiple levels simultaneously.
MOTS-C: The Mitochondrial Activator
Mechanism & Origin
MOTS-C (Mitochondrial-derived Peptide) is a 16-amino acid peptide encoded within the mitochondrial genome (small open reading frame location 12S rRNA). It functions as a master regulator of mitochondrial energy metabolism.
Key Identity Marker: Unlike most peptides, MOTS-C is encoded by mitochondrial DNA itself—it’s an intrinsic regulator of mitochondrial function, not an exogenous signal.
How MOTS-C Activates Energy Metabolism
-
AMPK Activation
– MOTS-C directly activates AMP-activated protein kinase (AMPK)
– AMPK is the cellular energy “sensor”—when activated, it tells the cell “conserve energy and increase energy production”
– AMPK upregulates mitochondrial biogenesis (making more mitochondria)
– AMPK enhances glucose and fatty acid oxidation (burning fuel more efficiently)
– AMPK suppresses mTOR, reducing anabolic (growth) signaling in favor of catabolic (energy-production) signaling -
Mitochondrial Biogenesis
– AMPK activation upregulates PGC-1α, the master regulator of mitochondrial biogenesis
– Result: increased mitochondrial quantity—cells literally build more mitochondrial copies
– More mitochondria = more capacity for ATP production -
Metabolic Flexibility
– MOTS-C enhances the cell’s ability to switch between fuel sources
– Can burn glucose, fatty acids, or ketones depending on availability
– This metabolic flexibility is characteristic of young, healthy metabolism
– Aging cells lose metabolic flexibility; MOTS-C restores it -
ROS Management
– By optimizing oxidative phosphorylation, MOTS-C reduces excessive reactive oxygen species (ROS) production
– Paradoxically: optimized mitochondrial function produces less ROS than dysfunctional mitochondria struggling to produce ATP
Research Timeline for MOTS-C
- Hours 0-6: AMPK activation begins
- Days 1-3: Mitochondrial biogenesis signals increase; metabolic flexibility begins improving
- Days 3-7: Increased mitochondrial quantity becomes measurable
- Weeks 2-4: Sustained elevated AMPK signaling; energy production metrics improve
- Weeks 4-8: Cumulative mitochondrial expansion and metabolic optimization
Critical context: MOTS-C works on mitochondrial biogenesis timelines. Benefits compound over weeks and months. This is not a “quick effect” peptide—it’s a foundational infrastructure rebuild.
SS-31: The Mitochondrial Protector
Mechanism & Origin
SS-31 (Bendavia or MTP-131) is a tetrapeptide (4 amino acids) designed specifically to target and stabilize the inner mitochondrial membrane. It’s one of the most mechanistically defined longevity peptides.
Key Identity Marker: SS-31 is a designer peptide—created specifically to address mitochondrial membrane dysfunction, not discovered as a natural compound.
How SS-31 Protects Mitochondrial Function
-
Cardiolipin Stabilization
– Cardiolipin is a unique phospholipid found exclusively in the inner mitochondrial membrane
– Cardiolipin is essential for electron transport chain (ETC) enzyme organization and function
– With age and oxidative stress, cardiolipin becomes oxidized—”cardiolipin peroxidation”
– Oxidized cardiolipin cannot organize ETC enzymes properly
– SS-31 selectively binds oxidized cardiolipin and restores its structural and functional properties
– This is extraordinarily specific: SS-31 targets the damaged form, not the healthy form -
Electron Transport Chain Optimization
– The ETC is where ATP is actually produced via oxidative phosphorylation
– Properly organized ETC enzymes are efficient; disorganized ones are inefficient and leak ROS
– By stabilizing cardiolipin, SS-31 ensures ETC enzymes stay optimally organized
– Result: more ATP produced per unit of oxygen consumed; less ROS generated -
Mitochondrial Potential Stabilization
– The mitochondrial membrane potential (voltage difference across inner membrane) drives ATP synthesis
– Cardiolipin oxidation destabilizes this potential
– SS-31 stabilization maintains optimal membrane potential
– This allows ATP synthase to work at peak efficiency -
Anti-Apoptotic Effects
– Dysfunctional mitochondria trigger apoptosis (cell death)
– By maintaining mitochondrial integrity, SS-31 prevents inappropriate cell death
– Aging involves widespread cell death due to mitochondrial dysfunction; SS-31 prevents this
Research Timeline for SS-31
- Hours 0-2: SS-31 crosses inner mitochondrial membrane and binds cardiolipin
- Hours 2-12: Cardiolipin stabilization begins; ETC function improves
- Days 1-3: Measurable improvements in ATP production; reduced ROS
- Days 3-7: Sustained ATP production optimization
- Weeks 2-4: Prevention of age-related mitochondrial decline
Critical context: SS-31 is a direct mitochondrial medicine. It acts locally at the inner membrane. Effects should manifest quickly (within hours-to-days), unlike MOTS-C’s mitochondrial biogenesis timeline.
Semax: The Neuroprotector
Mechanism & Origin
Semax is a heptapeptide (7 amino acids) derived from adrenocorticotropic hormone (ACTH). It functions as a master regulator of neurological signaling and cognitive function.
Key Identity Marker: Semax is extensively studied in Russian and Eastern European research contexts; it’s a foundational neuropeptide in aging research.
How Semax Supports Neurological Function
-
BDNF Upregulation
– Brain-derived neurotrophic factor (BDNF) is the primary signal that supports neuronal survival, growth, and synaptic plasticity
– BDNF declines with age—this is a hallmark of neurological aging
– Semax upregulates BDNF through CREB (cAMP response element binding protein) signaling
– Increased BDNF = improved neuroplasticity, better memory formation, enhanced cognitive function -
Neuroprotection Against Oxidative Stress
– The brain is particularly vulnerable to oxidative stress (ROS damage)
– Semax upregulates endogenous antioxidant systems (SOD, catalase, glutathione)
– Reduces neuroinflammation by suppressing excessive microglia activation
– Protects against neurodegeneration pathways -
Synaptic Plasticity Enhancement
– Synaptic plasticity—the ability of neural connections to strengthen or weaken—underlies learning and memory
– Semax enhances long-term potentiation (LTP), the cellular basis of memory formation
– Supports dendritic spine density (the connection points between neurons)
– With age, spine density declines; Semax preserves this critical neurological infrastructure -
Mood & Stress Response Modulation
– Semax influences monoamine signaling (dopamine, serotonin, norepinephrine)
– Supports HPA axis function (stress response regulation)
– Promotes mood stability and stress resilience -
Cerebral Blood Flow Support
– Semax enhances endothelial function in cerebral vessels
– Improves oxygen and nutrient delivery to brain tissue
– Supports cognitive function through enhanced vascular perfusion
Research Timeline for Semax
- Hours 0-6: BDNF signaling begins increasing
- Days 1-3: Measurable BDNF upregulation; neuroprotective signaling activates
- Days 3-7: Cognitive function improvements may become noticeable
- Weeks 2-4: Sustained neuroprotection; memory and cognitive enhancements compound
- Weeks 4-12: Long-term neuroplasticity optimization; age-related cognitive decline reversal
Critical context: Semax works on neurological timelines. Cognitive benefits compound over weeks. This is a foundational neuroprotection strategy, not an acute cognitive enhancer.
GHK-Cu: The Tissue Remodeler
Mechanism & Origin
GHK-Cu is a copper-bound tripeptide that acts as a master regulator of tissue remodeling and gene expression. (See the cornerstone guide for detailed mechanism; summary here focuses on longevity applications.)
How GHK-Cu Supports Longevity
-
Collagen Synthesis & Cross-Linking
– Collagen is the primary structural protein in skin, tendons, ligaments, blood vessels, and bone
– With age, collagen synthesis declines and existing collagen becomes less cross-linked
– GHK-Cu upregulates collagen synthesis via copper-dependent enzymatic activity
– Simultaneously promotes proper collagen cross-linking through lysyl oxidase activation
– Result: tissue becomes more elastic, strong, and resilient -
Gene Expression Orchestration
– GHK-Cu influences over 4,000 genes involved in tissue remodeling
– Net effect: favors repair, regeneration, and remodeling over senescence and decline
– TGF-β pathway activation supports fibroblast differentiation -
Vascular Function Support
– Vessel walls are composed largely of collagen and elastin
– GHK-Cu’s collagen enhancement directly improves vessel integrity
– Supports endothelial function and vasodilation
– Critical for maintaining the vascular system—the “highways” of aging -
Skin Integrity & Aging
– Skin aging is visible collagen/elastin breakdown and glycation
– GHK-Cu directly opposes these processes
– Supports skin barrier function, elasticity, and appearance
Research Timeline for GHK-Cu
- Hours 0-12: Gene expression changes begin
- Days 1-3: Collagen synthesis upregulation measurable
- Days 3-7: Tissue remodeling signals amplify
- Weeks 2-4: Visible improvements in tissue properties (skin, connective tissue)
- Weeks 4-12: Cumulative tissue optimization; age-related tissue decline arrest and potential reversal
The Longevity Quartet: Synergy Map
These four peptides target distinct, non-overlapping aging mechanisms:
┌─────────────────────────────────────────────────────────────┐
│ LONGEVITY QUARTET SYNERGY │
├─────────────────────────────────────────────────────────────┤
│ │
│ MOTS-C SS-31 │
│ └─ Mitochondrial └─ Mitochondrial │
│ Biogenesis ETC Stabilization │
│ (Build MORE) (Optimize EXISTING) │
│ ↓ ↓ │
│ Energy Production ←──────────┴──→ ATP Efficiency │
│ ↓ │
│ └────────────→ Reduced ROS ←────────────┘ │
│ ↓ │
│ Reduced Oxidative Stress │
│ ↓ │
│ ┌────────────────────┼────────────────────┐ │
│ ↓ ↓ ↓ │
│ Semax (ROS Control) GHK-Cu │
│ └─ Reduced supports all └─ Collagen │
│ Neuronal ROS neuropeptide Strength │
│ Damage function & and Repair │
│ protection │
│ ↓ ↓ │
│ Cognitive Tissue Integrity │
│ Preservation (Vascular, │
│ & Enhancement Skin, Bone) │
│ │
│ RESULT: Comprehensive, multi-system aging intervention │
│ Target: 4 key pathways with 0% mechanistic overlap │
│ │
└─────────────────────────────────────────────────────────────┘
Why Each Slot in the Quartet Matters
Remove MOTS-C: Lose mitochondrial biogenesis—no new mitochondria to replace aging ones
Remove SS-31: Lose acute mitochondrial optimization—ATP production remains suboptimal even with new mitochondria
Remove Semax: Lose neurological resilience—cognitive function declines despite healthy mitochondria elsewhere
Remove GHK-Cu: Lose tissue remodeling—structural aging (collagen, vascular) proceeds unchecked
All four together create a system: energy production optimized (MOTS-C + SS-31) → ROS controlled → neuroprotection enhanced (Semax) → tissue integrity maintained (GHK-Cu).
Research Protocols: Budget Frameworks
Budget Variant 1: Mitochondrial Focus
MOTS-C + SS-31
– Targets core energy production and ROS reduction
– Addresses the root cause (mitochondrial dysfunction) of much age-related decline
– Cost: $600-900/month
– Best for: those prioritizing energy, metabolic health, foundational aging intervention
– Coverage: ~60% of multi-system aging pathway
Budget Variant 2: Neuroprotection Priority
Semax + MOTS-C + SS-31
– Adds cognitive preservation to core mitochondrial support
– Addresses aging in brain tissue specifically
– Cost: $900-1,300/month
– Best for: cognitive longevity, neurological preservation, mood stability
– Coverage: ~80% of multi-system aging pathway
Budget Variant 3: Comprehensive Longevity Quartet
MOTS-C + SS-31 + Semax + GHK-Cu
– Full multi-system approach
– Targets mitochondrial energy, neuroprotection, and tissue integrity simultaneously
– Cost: $1,500-2,200/month
– Best for: comprehensive anti-aging strategy, those with existing age-related decline
– Coverage: ~95% of multi-system aging pathway
Timeline Expectations: Multi-Week Compounding
The Longevity Quartet works on overlapping timelines:
Weeks 1-2: Acute Mitochondrial Optimization
– SS-31 acts immediately; ETC function improves
– MOTS-C begins AMPK activation
– Semax starts BDNF upregulation
– Subjective: potentially improved energy, mood stability
Weeks 2-4: Biogenesis & Cumulative Effect
– MOTS-C mitochondrial biogenesis signals compound
– New mitochondria being synthesized
– Semax neuroprotection establishes itself
– GHK-Cu collagen synthesis upregulates
– Subjective: sustained energy improvements, cognitive clarity
Weeks 4-8: Infrastructure Expansion
– New mitochondrial quantity becomes measurable
– Neurological signaling optimization progresses
– Collagen remodeling becomes visible (skin, tissue quality)
– Cumulative ROS reduction supports all systems
– Objective: metabolic testing shows improved efficiency; cognitive testing shows improvement
Weeks 8-16: Maturation & Remodeling
– Mitochondrial expansion plateaus at optimized level
– Neuroprotection sustains cognitive gains
– Tissue remodeling matures—structural quality improves
– Age-related decline arrest and potential reversal across all systems
Published Research Landscape
MOTS-C: Emerging research shows mitochondrial-derived peptide effects on AMPK, metabolic health, and longevity. Small peptide field; growing literature.
SS-31: Extensive independent research on cardiolipin stabilization, mitochondrial function preservation, and translation to clinical contexts (Duchenne muscular dystrophy, heart disease).
Semax: Well-established in Russian and Eastern European research literature. BDNF upregulation documented. Neuroprotection effects in various neurological contexts studied extensively.
GHK-Cu: Extensive published research on gene expression, collagen synthesis, tissue remodeling. Recognized as foundational tissue regeneration peptide. Over 4,000 genes influenced well-documented.
Key Takeaway Box
The Longevity Quartet targets four non-overlapping aging pathways:
- MOTS-C: Mitochondrial biogenesis (build more mitochondria)
- SS-31: Mitochondrial optimization (optimize existing mitochondrial function)
- Semax: Neuroprotection (preserve cognitive function, BDNF signaling)
- GHK-Cu: Tissue remodeling (maintain collagen, vascular, connective tissue integrity)
Why all four together: Aging is multi-system. Single-target interventions address one bottleneck; the Longevity Quartet addresses four simultaneously with zero mechanistic overlap. Together they create comprehensive anti-aging intervention: optimized energy production (MOTS-C + SS-31) → ROS reduction → neurological preservation (Semax) → tissue integrity maintenance (GHK-Cu).
Timeline: Benefits compound over weeks and months. Weeks 1-2 show acute effects (SS-31, Semax); weeks 4-8 show biogenesis and tissue remodeling effects (MOTS-C, GHK-Cu); weeks 8-16 show mature optimization across all systems.
Common Questions
Q: Why these four peptides specifically?
Each occupies a distinct aging-biology axis: mitochondrial biogenesis (MOTS-C), mitochondrial optimization (SS-31), neuroprotection (Semax), tissue remodeling (GHK-Cu). The combination is mechanistically curated, not arbitrary — researchers can layer additional compounds (SLU-PP-332, 5-Amino-1MQ, BPC-157) but the quartet itself targets four non-overlapping pathways.
Q: Should all four be administered together?
Co-administration is the most straightforward research design, but sequential staging is also valid: front-load SS-31 + Semax for acute mitochondrial / neural effects (weeks 1-2), layer in MOTS-C and GHK-Cu for biogenesis / remodeling effects (weeks 4-8). The cascade dynamics inform research-protocol design.
Q: How does SLU-PP-332 fit in?
SLU-PP-332 is a small-molecule ERRα agonist with mitochondrial-biogenesis overlap with MOTS-C. Some research designs add it as a fifth compound; others compare it against MOTS-C to triangulate mechanism. See SLU-PP-332 deep dive.
Q: What COA verification matters most?
Each peptide has distinct verification needs: MOTS-C (sequence-specific MS), SS-31 (MS confirming the tetrapeptide cell-penetrating motif), Semax (heptapeptide MS), GHK-Cu (HPLC + atomic-absorption for copper stoichiometry). Standard ≥99% third-party HPLC applies across all four.
Q: How long do multi-system longevity protocols typically run?
12-16 weeks at minimum to capture biogenesis and remodeling-phase effects. Mitochondrial efficiency markers may shift earlier (weeks 2-4) but tissue remodeling and cognitive markers require longer windows. Published research designs increasingly use 6–12 month protocols.
Q: What’s the safety considerations for combining these peptides?
Each compound has favorable published safety profiles individually. Combination research designs should monitor standard endpoints (organ function, biomarkers, cognitive markers) and document any deviations. The compounds are mechanistically complementary, which limits direct interaction concerns.
Related Products
- MOTS-C — mitochondrial-derived peptide
- SS-31 — elamipretide cardiolipin-targeting tetrapeptide
- Semax — ACTH 4-10 analog cognitive peptide
- GHK-Cu — copper tripeptide tissue research compound
- SLU-PP-332 — exercise-mimetic ERRα agonist for layered designs
Related Research
- Complete Guide to Longevity Peptides 2026 — pillar
- Complete Guide to Anti-Aging Peptides 2026 — tissue-axis pairing
- Complete Guide to Cognitive Enhancement Peptides 2026 — neuro-axis pairing
- SLU-PP-332 Exercise Mimetic Deep Dive
- GHK-Cu Growth Surge — Anti-Aging Peptide
Last updated: May 20, 2026. For research purposes only. Not for human consumption. These statements have not been evaluated by the FDA.
